Abstracts tagged "Biologic agents"

Abstract Number: 598 • 2018 ACR/ARHP Annual Meeting
Real-World Experience of Effectiveness and Safety of Certolizumab Pegol for Rheumatoid Arthritis in Japan: Single-Center Retrospective Study
Naohiro Sugitani^1,2, Eiichi Tanaka¹, Eisuke Inoue^1,3, Eri Sugano¹, Kumiko Saka¹, Moeko Ochiai¹, Rei Yamaguchi¹, Yoko Shimizu¹, Naoki Sugimoto¹, Katsunori Ikari¹, Ayako Nakajima^1,2, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ³Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Certolizumab-pegol (CZP) is a sixth antitumor necrosis factor inhibitor for rheumatoid arthritis (RA) in Japan. Several clinical trials were conducted to evaluate the efficacy…
Abstract Number: 1887 • 2018 ACR/ARHP Annual Meeting
Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Gabriela Schmajuk^1,2, Michael Evans³, Julia Kay², Megan E. B. Clowse⁴, Esi Morgan⁵, Andreas Reimold⁶, Tracy Johansson⁷, Lindsay Lewis⁸ and Jinoos Yazdany⁹, ¹San Francisco VA Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, ³University of California - San Francisco, San Francisco, CA, ⁴Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ⁵University of Cincinnati, Cincinnati, OH, ⁶Rheumatology, University of TX Southwestern Medical Center, Dallas, TX, ⁷Practice, Advocacy & Quality, American College of Rheumatology, Atlanta, GA, ⁸American College of Rheumatology, Atlanta, GA, ⁹University of California, San Francisco, San Francisco, CA
Background/Purpose: Biologic DMARDs and tofacitinib account for a large proportion of drug spending in the U.S. Although TNFi drugs have dominated sales, use of…
Abstract Number: 2855 • 2018 ACR/ARHP Annual Meeting
Expanding the Phenotype: New Variant in the IL1RN-Gene Associated with Late Onset and Atypical Presentation of Dira
Jasmin B. Kuemmerle-Deschner¹, Konstanze Hoertnagel², Susanne Schlipf³, Sandra Hansmann⁴, Toni Hospach⁵, Ilias Tsiflikas⁶, Xiao Liu⁷, Susanne Benseler⁸ and Alexander Weber⁷, ¹Department of Pediatrics, Division of Rheumatology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ²Praxis für Humangenetik Tübingen,Tuebingen, Germany, Tuebingen, Germany, ³Kinderarztpraxis Dr. Lakner, Schwäbisch Gmünd, Germany, Schwäbisch Gmünd, Germany, ⁴Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tuebingen, Tuebingen, Germany, Tuebingen, Germany, ⁵Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgart, Germany, ⁶Division of Pediatric Radiology, Department of Radiology, University Hospital Tuebingen, Germany, Tuebingen, Germany, ⁷Department of Immunology, University of Tübingen, Tübingen, Germany, Tuebingen, Germany, ⁸Rheumatology, Department of Paediatrics, Alberta Children's Hospital, University of Calgary, Alberta, Canada, Calgary, AB, Canada
Background/Purpose: Deficiency of the Interleukin-1 receptor antagonist (DIRA) is an autoinflammatory disease of infancy characterized by severe systemic inflammation with bone and skin involvement. This…
Abstract Number: 611 • 2018 ACR/ARHP Annual Meeting
Influence of Dose Titration of Concomitant Steroid and Methotrexate during Biologic Therapy in Patients with Rheumatoid Arthritis in Daily Practice Based on the IORRA Cohort
Yoko Shimizu¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani^1,3, Moeko Ochiai¹, Rei Yamaguchi¹, Naoki Sugimoto¹, Ayako Nakajima^1,3, Katsunori Ikari¹, Atsuo Taniguchi¹ and Hisashi Yamanaka⁴, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan, ³Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, ⁴Institute of Rheumatology, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: After the introduction of Biological Disease-Modifying Anti-Rheumatic-Drugs (bDMARDs) for the treatment of patients with active rheumatoid arthritis (RA), clinical remission has become an achievable…
Abstract Number: 2311 • 2018 ACR/ARHP Annual Meeting
Effect of TNF Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients Receiving Bisphosphonate
Jung Sun Lee¹, Seokchan Hong², Doo-Ho Lim³, Jebum Won¹, Oh Chan Kwon², Ji Seon Oh², Yong-Gil Kim², Chang Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine,, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea, Republic of (South)
Background/Purpose: . This study aimed to investigate whether tumor necrosis factor inhibitors (TNFi) have beneficial effects on bone mineral density (BMD) in rheumatoid arthritis (RA)…
Abstract Number: 2876 • 2018 ACR/ARHP Annual Meeting
Torque Teno Virus Quantification for Functional Monitoring of Immunomodulation with Biological Compounds in the Treatment of Rheumatoid Arthritis
Paul Studenic¹, Gregor Bond², Andreas Kerschbaumer³, Manuel Bécède³, Karel Pavelka⁴, Dmitry Karateev⁵, Jutta Stieger⁶, Rudolf Puchner⁷, Ruediger Mueller⁸, Elisabeth Puchhammer-Stöckl⁹, Martina Durechova¹⁰, Michaela Loiskandl¹⁰, Thomas Perkmann¹¹, Marta Olejarova⁴, Elena Luchikhina¹², Carl-Walter Steiner¹³, Michael Bonelli¹⁰, Josef S. Smolen¹⁴ and Daniel Aletaha¹⁰, ¹Division of Rheumatology, Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Internal Medicine 3, Division of Nephrology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Experimental Rheumatology, 1st Faculty of Medicine, Institute of Rheumatology, Charles University in Prague, Prague, Czech Republic, ⁵Department of Rheumatology, Department of Rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ⁶2nd Deparment of Medicine, 2nd Deparment of Medicine, Hitzing Hospital, Vienna, Austria, ⁷Private Office, Wels, Austria, ⁸Division of Rheumatology, Immunology and Rehabilitation, Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St Gallen, St. Gallen, Switzerland, ⁹Institute for Virology, Institute for Virology, Medical University of Vienna, Vienna, Austria, ¹⁰Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹¹Department of Laboratory Medicine, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria, ¹²Department of rheumatology, Moscow Regional Research and Clinical Institute (MONIKI), Moscow, Russian Federation, ¹³Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid arthritis (RA) patients who fail to respond to methotrexate (MTX) can be subjected to an addition of biologic disease-modifying antirheumatic drug (bDMARD). Currently…
Abstract Number: 619 • 2018 ACR/ARHP Annual Meeting
Patterns of Change of a Second Biological Dmard in a Cohort of Patients with Rheumatoid Arthritis
Roger Rolon Campuzano¹, Andrea Lujan Coronel Ale², Osvaldo Cerda^3,4,5, Fernando Dal Pra⁶, Emilce E Schneeberger⁷, María de los Angeles Correa³, Marcos G. Rosemffet⁸, Emilio Buschiazzo⁹, Rodrigo García Salinas¹⁰, Silvia Beatriz Papasidero¹¹, Belén Barrios¹², Hernán Maldonado Ficco¹³ and Gustavo Citera², ¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ²Rheumatology Section, Instituto de Rehabilitación Psicofísica, CABA, Argentina, ³Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Staff, Buenos Aires, Argentina, ⁵Sociedad Argentina de Reumatologia, CABA, Argentina, ⁶Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁸Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁰Rheumatology Section, Hospital Italiano de La Plata, La Plata, Argentina, ¹¹Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Argentina, Buenos Aires, Argentina, ¹²Rheumatology section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, ¹³Rheumatology Section, Hospital San Antonio de Padua, Río Cuarto- Córdoba, Argentina
Background/Purpose: Evaluate the survival of the 2nd biological disease modifying drug (bDMARD)and to determine the causes of suspension of the 2nd bDMARD. Methods: Patients ≥…
Abstract Number: 2394 • 2018 ACR/ARHP Annual Meeting
Anti-Adalimumab Antibodies Kinetics: An Early Guide for Juvenile Idiopathic Arthritis (JIA) Switching
Juliana Brunelli¹, Clovis A Silva¹, Sandra G Pasoto², Carla GS Saad², Katia T. Kozu¹, Elaine P Leon², Margarete B Vendramini², Nicole Fontoura², Eloisa Bonfa³ and Nadia E Aikawa², ¹Pediatric Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Anti-adalimumab antibody (AAA) production may lead to reduced adalimumab (ADA) serum levels and therapy failure. There are, however, scarce and conflicting data regarding ADA…
Abstract Number: 2907 • 2018 ACR/ARHP Annual Meeting
Comparison of the Joints Ultrasonography in the Patients with Rheumatoid Arthritis Treated By Biological Agents and the Corresponding Synovial Histological Findings
Asami Abe¹, Hajime Ishikawa² and Kunihiko Wakaki³, ¹Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ²Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, ³Pathology, Niigata Prefectural Shibata Hospital, Shibata, Japan
Comparison of the joints ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Background/Purpose: In the treatment…
Abstract Number: 688 • 2018 ACR/ARHP Annual Meeting
Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
Andrea Shimabuco¹, Julio CB Moraes¹, Percival Sampaio-Barros², Cláudia Goldenstein-Schainberg¹, Celio R. Gonçalves¹, Ana CM Ribeiro¹ and Carla GS Saad¹, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use…
Abstract Number: 2449 • 2018 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry
Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors for serious infections (SIs) in rheumatoid arthritis (RA) patients receiving the biologic / target synthetic (b/ts) DMARDs.…
Abstract Number: 827 • 2018 ACR/ARHP Annual Meeting
Rituximab Therapy for Systemic Rheumatoid Vasculitis: Indications, Outcomes and Adverse Events
Caitrin Coffey¹, Michael Richter¹, Cynthia S. Crowson², Matthew J. Koster³, Kenneth J. Warrington⁴ and Ashima Makol³, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN
Background/Purpose: Rheumatoid vasculitis (RV) is a rare systemic inflammatory process affecting small to medium sized blood vessels in patients with rheumatoid arthritis (RA). RV confers…
Abstract Number: 2456 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Claudia A. Salinas¹, Lucy Mitchell², Jon T. Giles³, Thomas Dörner⁴ and Stephen P. Motsko¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapols, IN, ³Columbia University, College of Physicians and Surgeons, New York, NY, ⁴Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Patients with RA have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-RA populations1. …
Abstract Number: 1226 • 2018 ACR/ARHP Annual Meeting
Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis
Sho Fukui¹, Masei Suda², Haruki Sawada³, Yukihiko Ikeda¹, Mitsuru Watanabe⁴, Ayako Koido⁴, Rui Kawato⁵, Yasuhiro Suyama⁶, Hisanori Shimizu⁷, Haruyuki Yanaoka⁷, Ryo Rokutanda¹, Hiromichi Tamaki¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada⁹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ³Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁶Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, ⁷St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used and effective treatments for rheumatoid arthritis (RA), but generally biologics are avoided when patients have active infections on the day…
Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Pia Mercedes Lois¹, Cristina Vadillo Font¹, Dalifer Freites Núñez², Isabel Hernández-Rodríguez¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].